$XBI $93.43 | +5.48%
Covid Updates
$MRNA +6.2% Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax source
$NVAX +13.0% Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine source
$VERU +9.7% Veru Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome. source
$CLSN +18.1% Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate. source
Pipeline Updates
$VIRX +11.2% Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors. source
$HUMA +15.7% Humacyte Announces Clinical Case Series Demonstrating Potential of Human Acellular Vessel™ (HAV™) to Expand Opportunities for Limb Salvage in Multiple Complex Vascular Reconstruction Scenarios. source
$HTBX +11.0% Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services. source
$PFE -3.0% & $IONS +0.4% Pfizer and Ionis announce discontinuation of vupanorsen clinical development program. source
$ALT +12.1% Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity. source
$MDGL +2.1% Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health. source
$XERS +1.9% Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome. source
$TSHA +10.7% Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal Neuropathy. source
$ARAV +5.9% Aravive Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma. source
$PASG +6.8% Passage Bio to Showcase GM1 Gangliosidosis and Krabbe Clinical Programs at 2022 WORLDSymposium, February 7 – 11. source
$EGRX +1.2% Eagle Pharmaceuticals on Track to Support Submission of New Drug Application in Second Quarter 2022 for Landiolol, a Beta-1 Adrenergic Blocker. source
$RETA +12.9% Reata Pharmaceuticals Initiates Rolling Submission of New Drug Application with U.S. FDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia. source
$MNOV +6.6% MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada. source
$IDYA +6.6% IDEAYA Advances First-in-Class PARG Development Candidate, IDE161, into IND-Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide License. source
Business Updates
$ZYME +5.3% Zymeworks Announces Closing Of Public Offering And Exercise In Full Of The Underwriters’ Option To Purchase Additional Shares source
$GMDA +13.7% Gamida Cell Provides Key Program Updates and 2022 Financial Guidance. source
$NRXP -4.8% NRx Pharmaceuticals Announces $25 Million Private Placement Priced at a Premium to Market under Nasdaq Rules. source
Posted by FS/JM
留言